4 completed. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 3 |
Follow Infectious Mononucleosis: new trials by email Literature Review of Infectious Mononucleosis trials Research Report on Infectious Mononucleosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator - Epstein-Barr Virus Infection, Infectious Mononucleosis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2023-09-22 | 2026-04-22 |
| Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection Valomaciclovir, placebo - Infectious Mononucleosis | Phase 1 / Phase 2 | Completed | University of Minnesota | 23 | 2007-11-01 | 2017-03-22 |
| Controlled Trial of Valacyclovir in Infectious Mononucleosis valacyclovir - Infectious Mononucleosis | Phase 1 / Phase 2 | Completed | University of Minnesota | 20 | 2004-02-01 | 2011-10-27 |
| Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664). EBV vaccine (268664) - Epstein Barr Virus (EBV) Infection | Phase 2 | Completed | Henogen | 200 | 2007-02-02 |
Epstein-Barr Virus Infections (4) · Herpes Simplex (1) · Infections (1)
DNA Virus Infections (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Herpesviridae Infections (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Leukocyte Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Tumor Virus Infections (4) · Virus Diseases (4) · Infections (3) · Skin Diseases (1) · Skin Diseases, Infectious (1) · Skin Diseases, Viral (1)
Matrix-M (1) · Valacyclovir (1) · valomaciclovir (1)
University of Minnesota (2) · Henogen (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (3) · Belgium (1)
Henry H Balfour, MD (2) · Jessica R Durkee-Shock, M.D. (1)